Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.41 |
| ▸ | CDK1 | P06493 | 5/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392174 | 0.90 | AXL (0.43) | MEN1KMT2AMAPTPIK3CACYP3A4 | |
| SCHEMBL1391898 | 0.87 | CDK2 (0.43) | CDK2CCNE1CDK1CCNB1IKBKB | |
| SCHEMBL1391974 | 0.86 | CDK2 (0.42) | CDK2CCNE1CDK1CCNB1IKBKB | |
| SCHEMBL1391043 | 0.85 | EGFR (0.47) | MEN1KMT2AMAPTCDK2CCNE1 | |
| SCHEMBL1391784 | 0.83 | CCNE1 (0.46) | CDK2CCNE1CDK1CCNB1IKBKB | |
| SCHEMBL1391933 | 0.81 | CCNE1 (0.44) | MAPTCDK2CCNE1IKBKBUSP2 | |
| SCHEMBL1391093 | 0.79 | CDK2 (0.40) | PIK3CDPIK3R1PIK3CAPIK3CBCDK2 | |
| SCHEMBL1392103 | 0.78 | EGFR (0.46) | CDK2CCNE1CDK1CCNB1IKBKB | |
| SCHEMBL1391392 | 0.78 | LRRK2 (0.44) | CDK2CCNE1CDK1CCNB1IKBKB | |
| SCHEMBL1391256 | 0.77 | CCNE1 (0.43) | CDK2CCNE1CCNE2CCND1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | MEN1 4840/4885KMT2A 4066/4885MAPT 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.